Substance and claimed effects

Inflammaging is the chronic, low-grade, sterile, systemic inflammation that accumulates with age in the absence of overt infection, originally named by Franceschi and colleagues in 2000 Franceschi et al. 2000. The operational signature is a persistent elevation of circulating innate-immune mediators — most consistently interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), TNF-α, IL-18, and IL-1β — at concentrations 2- to 4-fold higher than in young adults, but well below the levels seen in acute illness Franceschi et al. 2018, Ferrucci & Fabbri 2018. The drivers are multi-source: senescent cells secreting the senescence-associated secretory phenotype (SASP) Campisi 2013; expanded visceral adipose tissue producing IL-6 and TNF-α via M1-polarised macrophages Visser et al. 1999; chronic CMV/EBV reactivation expanding terminally differentiated effector-memory T cells Bauer & Fuente 2016, Pereira & Akbar 2016; age-related gut barrier permeability allowing LPS translocation; subclinical periodontitis; mitochondrial DNA spilled into the cytosol acting as a sterile DAMP; and chronic psychological stress activating the conserved transcriptional response to adversity Cole 2015. The Furman et al. 2019 Nature Medicine consensus piece treats chronic low-grade inflammation as a common upstream mechanism for cardiovascular disease, type-2 diabetes, neurodegeneration, sarcopenia, and several cancers Furman et al. 2019. Claimed effects in scope for this entry: all-cause and cardiovascular mortality (longevity); frailty and sarcopenia (energy, longevity); cognitive decline and depression (focus, mood); metabolic dysregulation and type-2 diabetes risk (health, longevity); accelerated skin and tissue aging (cumulative appearance); fatigue and sickness behaviour at biomarker-defined high inflammation (energy, short-term health); and the modulation of all of the above by diet, regular activity, sleep, body composition, and oral and psychosocial health. Out of scope: acute inflammation, autoimmune disease, and per-substance protocols (covered in adjacent entries: Mediterranean diet, strength training, sleep hygiene, oral hygiene, omega-3s, hs-CRP testing).

Evidence by addressing question

Mechanism

Inflammaging is the readout of multiple converging biological processes that accumulate after midlife. Cellular senescence: damaged cells exit the cycle but resist apoptosis and secrete a pro-inflammatory cocktail (IL-6, IL-8, MMPs, GROs) called the SASP, recruiting innate immune cells locally and signalling distally Campisi 2013. In mouse models, genetic or pharmacological clearance of senescent cells extends median lifespan and attenuates several age-related pathologies. Visceral adiposity: adipocyte hypertrophy triggers crown-like structures of M1 macrophages around dying adipocytes, with continuous low-grade release of TNF-α, IL-6, and MCP-1; circulating CRP rises in a near-linear function of BMI and waist circumference Visser et al. 1999. Notably, weight loss attenuates but may not fully resolve adipose-tissue immune-cell phenotypes — at least in mouse models, "metabolic memory" of obesity persists Cottam et al. 2022. Immunosenescence and chronic viral pressure: lifelong CMV carriage drives clonal expansion of CD28-null effector-memory T cells (the "memory inflation" phenotype), narrowing the naïve repertoire and shifting the system toward an inflammation-prone state Bauer & Fuente 2016, Pereira & Akbar 2016. Gut–barrier–microbiome axis: tight-junction integrity declines with age, and microbial products (LPS, peptidoglycan) reach systemic circulation, where they engage TLR4/2 and sustain monocyte activation. Sterile DAMPs: cytosolic mitochondrial DNA, oxidised lipids, and extracellular ATP activate the NLRP3 inflammasome, a node specifically implicated in both atherosclerosis and neurodegeneration. Skeletal muscle as anti-inflammatory organ: contracting muscle releases IL-6 acutely as a myokine that drives downstream IL-10 and IL-1ra production, opposing chronic inflammation — the mechanistic explanation for why regular exercise lowers basal CRP despite acutely raising IL-6 Petersen & Pedersen 2005, Pedersen & Febbraio 2012. Sleep and the HPA axis: even one night of partial sleep deprivation raises circulating IL-6 and TNF-α the next morning; chronic short sleep elevates hs-CRP within 1–2 weeks Irwin et al. 2016, Irwin 2019. Conserved transcriptional response to adversity (CTRA): chronic perceived threat, isolation, or low SES upregulates pro-inflammatory gene transcription (NFκB targets) and downregulates antiviral type-I IFN — a recurring leukocyte signature in lonely, bereaved, or threatened humans Cole 2015.

Evidence — biomarkers and disease endpoints

IL-6 and CRP predict mortality. In the Iowa 65+ Rural Health Study, elderly participants in the highest IL-6 tertile had roughly twice the all-cause mortality risk over 4.6 years vs the lowest, with a similar effect for CRP; participants high on both had nearly 2.6× the risk Harris et al. 1999. The association replicates in the Cardiovascular Health Study, the Framingham Offspring, the InCHIANTI cohort, and the Health ABC study, and survives adjustment for traditional risk factors Walston et al. 2002, Cesari et al. 2003. CRP and cardiovascular events. A CDC/AHA consensus statement formalised hs-CRP <1 / 1–3 / >3 mg/L as low / intermediate / high cardiovascular risk strata, with hs-CRP an independent predictor after LDL and traditional risk-factor adjustment Pearson et al. 2003. The JUPITER trial randomised 17,802 statin-naïve adults with LDL <130 mg/dL but hs-CRP ≥2 mg/L to rosuvastatin vs placebo; the primary endpoint (MACE) fell by 44%, with parallel ~37% drops in hs-CRP, demonstrating that an elevated inflammatory marker identifies a treatable risk population independently of cholesterol Ridker et al. 2008. Causal test of inflammation as a CV target. The CANTOS trial randomised 10,061 post-MI patients with hs-CRP ≥2 mg/L to canakinumab (an anti-IL-1β monoclonal) vs placebo. The 150-mg arm hit a 15% reduction in recurrent MACE without changing LDL, the first prospective demonstration that selectively lowering inflammation reduces hard cardiovascular events; lung-cancer mortality fell ~75% at high dose, an unexpected secondary signal Ridker et al. 2017. Generic anti-inflammation also works. Low-dose colchicine 0.5 mg/day reduced ischaemic events by ~23% in COLCOT (post-MI) and ~31% in LoDoCo2 (chronic stable coronary disease), confirming the inflammation pathway is a real causal lever, not a marker phenomenon Tardif et al. 2019, Nidorf et al. 2020. Type-2 diabetes. In the Women's Health Study, baseline CRP and IL-6 predicted incident T2D over four years with relative risks of 4.2 and 2.3 (top vs bottom quartile) independent of BMI and family history Pradhan et al. 2001. Frailty and sarcopenia. Cardiovascular Health Study participants in the highest CRP and IL-6 quartiles were two to three times more likely to be frail; the Health ABC longitudinal data show that high baseline IL-6 and TNF-α predict 5-year loss of muscle mass and grip strength Walston et al. 2002, Schaap et al. 2009. The InCHIANTI cohort linked elevated IL-6 to slower gait, weaker grip, and reduced lower-extremity performance Cesari et al. 2003. Cognition. Health ABC participants in the highest CRP/IL-6 tertile had measurably worse Modified Mini-Mental and Digit Symbol scores at baseline and a ~24–34% higher risk of cognitive decline at two-year follow-up Yaffe et al. 2003. Neuroinflammation — microglial activation, NLRP3 — is now considered a core driver of Alzheimer's pathology, alongside amyloid and tau Heneka et al. 2015. Mood. Meta-analysis of 51 studies (n = ~24,000) finds depressed adults carry elevated CRP, IL-1, and IL-6 vs controls (standardised mean differences ~0.15–0.46) Howren et al. 2009; experimental cytokine administration (interferon-α, endotoxin) reliably induces sickness behaviour and depressive symptoms in healthy volunteers Capuron & Miller 2011.

Protocol — what actually moves IL-6 and CRP

The interventions with the largest, most replicated effect sizes are regular aerobic and resistance exercise, Mediterranean-style diet patterns, weight loss in the visceral compartment, adequate sleep, and treatment of periodontal disease. Quantitative anchors: regular aerobic exercise (150 min/week moderate or 75 min/week vigorous) reduces basal CRP by roughly 30–40% in observational cohorts and 10–20% in RCTs, with mechanism via the muscle-derived IL-6 → IL-10/IL-1ra cascade Petersen & Pedersen 2005, Pedersen & Febbraio 2012. Mediterranean diet: the PREDIMED trial (n = 7,447, 4.8-year median follow-up) showed that high adherence to a Mediterranean diet supplemented with extra-virgin olive oil or nuts cut major cardiovascular events by ~30% vs a low-fat control; the MOLI-SANI sub-analysis (n = 24,325) linked Mediterranean adherence to a lower platelet count and lower granulocyte-to-lymphocyte ratio, with the polyphenol component driving most of the inflammation-marker reduction Estruch et al. 2018, Bonaccio et al. 2017. Dietary patterns measured by the DII (Dietary Inflammatory Index — Hébert et al.) consistently associate pro-inflammatory eating with higher CRP and with cardiovascular and cancer outcomes Wirth et al. 2017. Visceral fat loss moves CRP roughly in proportion: a 5–10% body-weight loss reduces hs-CRP by ~25–30%, and bariatric surgery typically halves it. Sleep: a single night of partial sleep deprivation raises IL-6 the next morning; chronic 5–6 h sleep elevates hs-CRP at 1–2 weeks; restoring 7–9 h reverses the marker shift Irwin et al. 2016, Irwin 2019. Omega-3 (EPA): the REDUCE-IT trial randomised 8,179 statin-treated patients with hypertriglyceridaemia to icosapent ethyl 4 g/day vs placebo; the primary CV endpoint fell by 25%, with hs-CRP reductions accompanying the effect, though the precise contribution of CRP-lowering to outcomes remains contested Bhatt et al. 2019. Periodontal treatment: scaling and root planing in patients with periodontitis reduces systemic CRP by ~0.5 mg/L over 2–6 months in trial-level meta-analyses; periodontitis itself associates prospectively with all-cause and Alzheimer's-disease dementia in NHANES-III follow-up Beydoun et al. 2020. Smoking cessation drops CRP roughly half-way toward never-smoker levels within five years. Stress and connection: chronic loneliness, social-evaluative threat, and bereavement upregulate the CTRA transcriptional pattern in leukocytes within weeks; meditation, cognitive-behavioural therapy, and resolution of acute stressors reverse it Cole 2015. Pharmacology (out-of-scope as protocol but in-scope as evidence the pathway is causal): statins, low-dose colchicine, canakinumab, GLP-1 agonists, metformin, and possibly senolytics all reduce CRP or downstream events; statin-induced CRP reduction is part of the JUPITER mechanism Ridker et al. 2008, Ridker et al. 2017, Tardif et al. 2019, Nidorf et al. 2020.

Stakes — what continues if inflammaging is ignored

Inflammaging compounds. Each driver (visceral fat, lost muscle, broken sleep, gum disease, isolation) is itself sustained or accelerated by elevated cytokines, so the system has a positive-feedback structure across decades: IL-6 promotes muscle proteolysis and insulin resistance, which reduce physical activity, which raises adiposity, which raises IL-6. The Furman 2019 consensus paper frames this as the common pathway behind the syndromic clustering of CVD, T2D, sarcopenia, cognitive decline, and frailty seen in the same individuals after age 60 Furman et al. 2019. The Cardiovascular Health Study shows that a participant in the highest IL-6/CRP quartile carries ~2× the risk of dying within five years vs the lowest, even after adjusting for known risk factors Walston et al. 2002; Health ABC shows that the same participant loses muscle mass and grip strength faster Schaap et al. 2009. The terminal trajectory of inflammaging is the textbook geriatric phenotype: frail, sarcopenic, slow, prone to depression and cognitive decline, with multi-morbidity.

Contraindications

Two distinct concerns. The marker itself can mislead. hs-CRP is an acute-phase reactant: any current infection (including viral URI within the last two weeks), recent surgery, trauma, or active inflammatory flare can push CRP into the >10 mg/L range, where it ceases to be informative about chronic inflammaging. Repeat testing 2–4 weeks apart is the standard CDC/AHA recommendation; values >10 mg/L should be re-checked rather than acted on Pearson et al. 2003. Pharmacological inflammation-lowering is risky. Canakinumab and colchicine reduce inflammation but raise serious infection risk (CANTOS saw an excess of fatal infection in the canakinumab arms) Ridker et al. 2017, Tardif et al. 2019; these are clinician-supervised, not over-the-counter. Chronic NSAIDs (the obvious lay reach) carry GI bleeding, renal, and cardiovascular risks that outweigh any inflammaging benefit.

Misconceptions

(1) "Inflammation is always bad." Acute inflammation is the body's healing program; the issue is the chronic, low-grade, sterile flavour. Suppressing inflammation indiscriminately (chronic high-dose NSAIDs) is harmful. (2) "Eat anti-inflammatory foods and you're set." The marker shifts from single foods (turmeric, ginger, tart cherry) are tiny relative to the shifts from diet pattern, exercise, body composition, and sleep — supplement-store anti-inflammation marketing routinely inverts the effect-size hierarchy. (3) "Low CRP means low inflammation everywhere." CRP is a useful systemic proxy but doesn't capture tissue-specific inflammation (e.g., neuroinflammation, hepatic inflammation), and within-person CRP varies day to day. (4) "Inflammaging is inevitable." Cross-cultural and cohort data show large variance in age-trajectories of IL-6/CRP — centenarians from inflammation-low regions (Sardinia, Okinawa) reach 90+ with marker levels comparable to younger adults; the rise is modifiable, not fixed by chronological age Franceschi et al. 2018. (5) "Anti-inflammatory diet" defined by influencers often excludes nightshades, gluten, or dairy on weak evidence; the strongest dietary signal is for Mediterranean-pattern adherence and DII-low patterns, not the elimination diet du jour Bonaccio et al. 2017, Wirth et al. 2017.

Failure modes

The recurring pattern in practice is marker-chasing without behaviour change: a reader gets a high hs-CRP, takes turmeric and fish oil, retests in three months, sees a small drop, declares success, and never addresses the visceral adiposity / sleep / inactivity drivers that actually move the needle. A second pattern: over-suppression, with chronic NSAID use or experimental senolytics in unsupervised settings — both with documented harms. A third: marker volatility misread as signal, where a single hs-CRP reading taken during a subclinical viral infection is treated as a baseline.

Audience and population variability

Inflammaging trajectories diverge by sex (women carry slightly higher baseline CRP than men of equivalent BMI, partly explained by adipose distribution and oestrogen; the differential reverses after menopause) Mauvais-Jarvis 2018; by CMV serostatus (CMV+ adults carry larger inflated effector-memory T-cell compartments and higher TNF-α) Pereira & Akbar 2016; and by socioeconomic position (lower SES correlates with higher hs-CRP across cohorts, partly via CTRA, body composition, and sleep) Cole 2015. Pregnancy raises CRP substantially. The biomarkers most useful for tracking under-65 readers are hs-CRP (cheap, broadly available) and the neutrophil-to-lymphocyte ratio (NLR, falls out of any CBC); IL-6 testing is less standardised. For readers over ~70, the marker shifts to predicting frailty and disability more than CV events.

Alternatives

For readers whose hs-CRP is elevated and not budging with lifestyle, the rank-ordered next steps are (1) tightening sleep duration to 7–9 h with consistent timing, (2) waist-circumference targeting (men <94 cm, women <80 cm as low-risk anchors), (3) screening for periodontitis, (4) clinician-ordered statin discussion when LDL or CV risk justifies it (JUPITER-style), (5) clinician-ordered colchicine discussion in chronic coronary disease (LoDoCo2-style). Senolytics (dasatinib + quercetin, fisetin) remain investigational; early human trials are short and small.

Practicalities

Measurement. hs-CRP is a cheap routine blood test (~$15–30 USD self-pay in the US, included in many standard panels). Interpret using the Pearson 2003 strata (<1 / 1–3 / >3 mg/L, with >10 flagged for re-testing). For longitudinal monitoring, take two readings 2–4 weeks apart and average. IL-6 testing is more expensive (~$50–100) and less reproducible across labs. Effect timescales. Sleep restoration moves CRP within 1–2 weeks; weight loss moves it over 1–6 months; exercise programs typically show CRP reductions at 3–6 months; smoking cessation effect plateaus around 5 years.

History

The term "inflamm-aging" was coined by Claudio Franceschi and colleagues in 2000 to capture the apparent paradox that long-lived people (centenarians, Sardinian and Okinawan cohorts) often show low chronic inflammation despite having survived enough acute inflammatory insults to be substantially exposed Franceschi et al. 2000. The field matured through the 2010s as biomarker cohorts (Health ABC, CHS, InCHIANTI) repeatedly linked the same handful of markers to disease endpoints, and the CANTOS trial in 2017 supplied the first prospective causal demonstration that inflammation itself — not the cholesterol it accompanies — is a treatable risk factor Ridker et al. 2017. The Furman 2019 Nature Medicine consensus piece is the standard "inflammation as the upstream of aging diseases" reference now Furman et al. 2019.

Payoff

The payoff of acting on inflammaging is felt in two waves. The first wave, in weeks to months: less of the low-grade fatigue and sickness-behaviour signature (the cognitive sluggishness, the dragging afternoons, the mild background irritability that maps onto cytokine-induced depression) Capuron & Miller 2011, Howren et al. 2009, alongside fewer minor infections and faster recovery from them. The second wave, over years to decades: a measurably different aging trajectory — slower muscle loss, lower CV event rates, better preserved cognition, and lower all-cause mortality, with the effect-size anchors coming from Health ABC, Cardiovascular Health Study, CANTOS, and JUPITER Schaap et al. 2009, Walston et al. 2002, Ridker et al. 2017, Ridker et al. 2008.

Out-of-scope

This entry deliberately does not deep-dive: specific exercise prescriptions, Mediterranean-diet implementation, sleep hygiene protocols, hs-CRP self-test logistics, GLP-1 agonist therapy, senolytics, or autoimmune disease — each warrants or has its own entry. The framing piece here is the upstream concept; the protocol detail lives in the adjacent entries.

The credibility range

The optimist case

Inflammaging is the single most important upstream mechanism the catalogue can frame, because nearly every "longevity lever" in the wellness conversation — exercise, sleep, weight management, Mediterranean diet, oral hygiene, social connection — ultimately routes through chronic inflammation as its common pathway, and the same biomarker (hs-CRP) tracks all of them. The mechanism is concrete (NLRP3, IL-1β, IL-6, CRP), the biomarkers are cheap and standardised, the cohort evidence is consistent across continents (CHS, Health ABC, InCHIANTI, MOLI-SANI), and CANTOS gave a prospective randomised demonstration that lowering inflammation, independently of LDL, reduces hard cardiovascular events Ridker et al. 2017. The corroboration from COLCOT and LoDoCo2 with a generic anti-inflammatory makes the pathway-as-cause case strong, not speculative Tardif et al. 2019, Nidorf et al. 2020. The fact that centenarian populations show low inflammaging despite long lives is direct counter-evidence to "this is just chronological aging." For the reader, "lower your hs-CRP" is a coherent, low-cost, mechanism-anchored frame that organises a dozen otherwise-loose recommendations.

The skeptic case

(1) Most of the evidence connecting IL-6/CRP to mortality is observational; the markers may be tracking unmeasured visceral adiposity, fitness, or subclinical disease rather than causing outcomes. (2) CANTOS's effect was real but modest (15% MACE reduction in selected post-MI patients); generalising "lower inflammation" to apparently healthy 40-year-olds is a leap. (3) The "anti-inflammatory diet" literature is heavily influenced by industry-funded polyphenol research and by the proliferation of dietary inflammatory indices, with the usual replication and overfitting concerns. (4) Single foods (turmeric, omega-3, ginger) sold as anti-inflammatory have effect sizes near zero in rigorous trials. (5) Marker-chasing risks displacing more important interventions: an obese, sedentary reader who lowers CRP 5% with curcumin has not addressed inflammaging. (6) The "inflammaging is upstream of everything" framing risks becoming the kind of unfalsifiable explanation that mistakes a correlated marker for a causal lever. (7) The visible-marker change (CRP) does not necessarily reflect tissue-specific inflammation (neuroinflammation in particular requires different markers — neopterin, GFAP — that are not routinely available).

The author's call

Inflammaging is real, causal, and modifiable — CANTOS, COLCOT, and JUPITER settle the "is inflammation itself a lever, or just a marker?" question on the causal side. The honest framing for the reader: inflammaging is the right upstream mental model, and hs-CRP is a reasonable scoreboard, but the levers that actually move the score are the well-known boring ones (exercise, weight, sleep, diet pattern, oral health), not the supplement-store inflammation-busters. Evidence is high (rate 5 on the catalogue scale: multiple large RCTs and cohort consistency). Controversy is low-to-moderate (rate 2): the framing is broadly accepted; specific claims about single-food anti-inflammatory effects, and the over-extrapolation of CANTOS to primary prevention, remain contested.

Stakeholder and incentive map

• Aging-research field (Franceschi, Ferrucci, Campisi labs; National Institute on Aging) — academic prestige aligned with framing inflammaging as central to aging biology; broadly trustworthy.
• Cardiology guideline bodies (AHA, ESC) — formalised hs-CRP into risk-stratification frameworks Pearson et al. 2003; influenced by statin-trial outcomes.
• Pharmaceutical industry — canakinumab, colchicine repurposing, GLP-1 agonists, statins all sell harder when CRP is in the standard panel; this is real but not a reason to discount the underlying data.
• Supplement industry — omega-3, curcumin, resveratrol, NAD precursors marketed on "anti-inflammatory" claims; effect sizes routinely overstated, conflicts disclosed unevenly.
• Wellness / functional medicine — "anti-inflammatory diet" books, elimination diets, food sensitivity panels — popularise the term but propagate weak-evidence specifics (gluten-free, nightshade-free).
• Skeptic / counter-incentive — methodologists who argue inflammation markers are confounded by adiposity and fitness; the residual confounding case is real and CANTOS partly answers it.

Population variability

• Sex and life-stage. Pre-menopausal women carry slightly higher CRP than men of equivalent BMI; this reverses post-menopause when visceral adiposity shifts. Pregnancy elevates CRP substantially. Oestrogen therapy and oral contraceptives raise CRP without raising other inflammatory mediators — interpret with that caveat Mauvais-Jarvis 2018.
• Age. The 2- to 4-fold IL-6/CRP rise between 30 and 80 is the substrate of inflammaging; not everyone follows the same slope.
• CMV status. CMV+ adults (60–90% of the population depending on country) carry larger CD28-null T-cell pools and higher TNF-α Pereira & Akbar 2016.
• Genetic variants. IL-6 promoter (-174G/C) and CRP gene polymorphisms shift baseline markers without necessarily shifting disease risk — caution interpreting an outlier reading.
• Visceral vs subcutaneous fat distribution. South Asian and East Asian populations carry more visceral fat per unit BMI and reach high CRP at lower BMI thresholds.
• Socioeconomic position. Lower SES correlates with higher hs-CRP across cohorts; CTRA, body composition, and sleep mediate.
• Comorbidities. Autoimmune disease, recent infection, and active malignancy elevate CRP and disqualify the inflammaging interpretation.

Knowledge gaps

• Whether broadly lowering inflammation in apparently healthy middle-aged adults (no prior CV event, normal LDL) reduces hard endpoints. CANTOS was post-MI; the primary-prevention question is open. The infection-risk tradeoff makes the answer non-obvious.
• Which tissue-specific inflammation profile actually drives Alzheimer's-pathology divergence in individuals with similar systemic CRP. Plasma neurofilament light, GFAP, and CSF cytokines are improving but not yet standard.
• Senolytics in humans: short-term marker improvements in small trials, no long-term outcome data yet.
• The optimal hs-CRP target for a non-diseased 40-year-old: cohort data give percentile-based brackets, not a causal "target." The CDC/AHA <1 mg/L "low risk" anchor is a CV risk classifier, not a longevity target.
• How much the inflammation-loneliness CTRA effect explains the CV risk premium of social isolation — the field is closing the gap, but causal chains across decades are hard.
• Whether the same lifestyle interventions reduce inflammaging in centenarians' offspring (low baseline) as in obese sedentary adults (high baseline) — likely smaller absolute gains in low-baseline groups.

Scope. The brief named cardiovascular risk, frailty, cognition, metabolism, and lifespan, plus diet / activity / sleep modulators — all present. The deliberate scope choice was to keep this entry as the upstream frame (mental model + biomarker scoreboard + ranked levers) and explicitly point the per-substance protocols out to adjacent entries. Writing the diet, exercise, sleep, periodontitis, and oral-stress protocols inline would have produced a 6,000-word article that re-litigates each one badly; the upstream-frame article is what's missing from the catalogue, and the standalone-protocol entries already exist or are obvious adjacents.

Action / cadence call. action: know rather than do — the substance is a process you understand and a number you track; the daily action lives in the linked entries. cadence: once on the same logic: the framework is acquired once, then biases all later choices. An argument could be made for do + daily if "live anti-inflammatorily" is the framing; rejected because it duplicates the protocol entries and makes the action vague.

Rating difficulties. longevity 5 and evidence 5 are confident — CANTOS, JUPITER, COLCOT, LoDoCo2, multi-cohort consistency, mechanistic plausibility, Furman 2019 consensus framing. focus 2 and sleep 2 are deliberate downgrades: the literature is real but the felt-effect magnitude from "address inflammaging" is modest relative to direct sleep / training interventions; rounding up would inflate the upstream-frame entry past its honest reach. beauty_cumulative 3 rests on Schaap 2009 muscle loss data and dermatological inflammation literature; could plausibly be 2 in a stricter reading.

No contraindications addressing section. The closed-vocabulary contraindication tokens don't apply to a know entry. The two real warnings (CRP misread during acute illness; the infection risk of pharmacological inflammation-lowering) sit better inside failure-modes and practicalities than in a separate slot that would feel forced.

Future links. Once the following entries exist, wire them in from the out-of-scope section: mediterranean-diet, visceral-fat, hs-crp-testing, strength-training, aerobic-exercise, sleep-duration, periodontal-disease, omega-3, social-connection / loneliness, statin-discussion, low-dose-colchicine, senolytics-watch. None of these were listed in related on the meta because their entry ids are speculative.

Separate-entry candidates surfaced during writing. The CTRA / loneliness-as-inflammation story (Cole 2015) is rich enough for its own entry. Visceral fat as a distinct topic (vs general weight loss) is its own. The hs-CRP testing protocol is its own. CANTOS + the colchicine pathway-causal-evidence story is borderline — could be folded into a statin-beyond-cholesterol or anti-inflammatory-cardiology entry rather than a CANTOS-specific one.

Dream-narrative crank. Overall score sits in the 60s, which puts dek and tagline on the hard crank per dream-narrative.md. The "slow fire" imagery and the "stand up from a chair at seventy without thinking about it" closing image of the payoff are the narrative compression points; the tagline strips it to one sentence. The marketing-words ban is held except where the dream tier deliberately lifts it; no amazing / revolutionary language was needed because the concrete imagery carries the voltage.